Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Allergan | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Allergan

Loss in the quarter impacted by divestitures, lost exclusivity, and a decline in RESTASIS

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Allergan
4Q Revenues: $4.1 billion (-6%)
4Q Loss: $4.3 billion (earnings were $3.1 billion 4Q17)
FY Revenues: $15.8 billion (-1%)
FY Loss: $5.1 billion (loss of $4.1 billion FY17)
Comments: Loss in the quarter was impacted by divestitures, products that lost exclusivity and a decline in RESTASIS (down 19% to $325 million) due to lower demand and net pricing, as well as the divestiture of the company’s Medical Dermatology business in September 2018. BOTOX Therapeutic (Neurosciences & Urology) revenues in the quarter were $433.3 million, up 13%. U.S. General Medicine revenues in the quarter were $1.4 billion, down 8%, impacted by lower revenues from NAMENDA XR and ESTRACE due to generic competition, offset by growth from VRAYLAR and Lo LOESTRIN.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters